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Introduction: Castleman’s disease (CD) is a rare benign disorder that may grow in any area where
lymphoid tissue is normally present but the most frequent site is mediastinum (67%); the abdomen is
rarely affected by this pathology. In the pathogenesis of CD an important role could be played by HHV-8.
Diagnosis is difﬁcult and the diagnostic certainty is obtained only by histological examination. For this
disease there is no gold-standard treatment.
Case report: We report the case of a woman of 33 years of age affected by a rare form of abdominal nodal
localization of Castleman’s Disease for which the patient underwent surgery.
Conclusion: CD must be included in the differential diagnosis of retroperitoneal tumors even though the
deﬁnitive diagnosis can only be achieved by histological and immunohistochemical examination. In the
case of single location, the treatment of choice is surgical removal.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Castleman’s disease is a rare proliferative disorder of a benign
nature characterized by hyperplasia of lymphoid follicles.1,2 The
most frequent location of the CD is the chest (70%) although this
pathology can theoretically affect any nodal station.2 The abdomen
is rarely affected by this pathology, abdominal localizations repor-
ted in the literature are: mesentery, retroperitoneum, pancreas,
pelvis and rectum.3
Diagnosis is difﬁcult and the diagnostic certainty is obtained
only by histological examination. For this disease there is no gold-
standard treatment.
2. Case report
A 33-year old woman with a silent pathology history, was
referred to us for weight loss (about 3 kg) and epigastric pain
radiated to the right side and rear in the lumbar region. The
abdominal examination did not reveal anything pathological.
The blood tests did not show anything at the pathological level and
the tumormarkers were normal, as were the results of chest X-rays.
The abdominal ultrasound detected the presence in the right
epigastric region a hypoechogenic image, homogeneous, round, sur-
rounded by a hyperechogenic capsule (max diameter 31 mm),ianto di Fegato, D.E.T.O., Uni-
ly. Tel.: þ39 0805593221.
i).
ciates Ltd. Published by Elsevier Ltcompressing from behind the ICV, laterally the gallbladder and
contracts with the head of the pancreas. Given the inconsistency in
interpretation and in order to obtain more detailed information a CT
scamof theabdomenwascarriedout and this conﬁrmed thepresence
between aorta and ICV, at the level of the duodenal C knee, a forma-
tion of 3 cm oval with homogeneous enhancement similar to after
injection of intravenous contrast medium and the radiologist sug-
gested that it was a leiomioma of the duodenal wall. In history the
patienthad reported repeatedepisodes of herpetic infection localized
in the lip. The detection of the anti-HHV-8 antibodies was successful
because the patient had serum antibodies against the virus.
The patient then underwent surgery of the formation. In the
operating ﬁeld there was nothing pathological as regards the
stomach and duodenum. However, in the retroperitoneal location,
below the third duodenal portion, in the paracaval site, there was
a found a smooth, ovular, taught-elastic formation (Figs. 1 and 2).
No retroperitoneal adenopathy was detected.
The histological examination showed that the lymph node was
a neo-formation and this allowed us to make a diagnosis of Cas-
tleman’s disease with vascular ialino-positive immunohistochem-
ical reaction for CD-20 CD-3, CD-138 and Ki-67 (Figs. 3 and 4).
After a clinical course without complications, the patient was
discharged and is currently in good health.
3. Discussion
Castleman’s disease is a rare benign disorder ﬁrst described by
Castleman in 1954 in a group of patients with mediastinal
lymphoadenopathy.2,4d. All rights reserved.
Fig. 1. Gross ﬁndings of lymph node. Fig. 3. Microscopic ﬁndings of lymph node.
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tissue is normally present but the most frequent is mediastinal
(67%),5 the abdomen is rarely affected by this pathology; abdominal
localizations reported in the literature are: mesentery, retro-
peritoneum, pancreas, pelvis, rectum, however, being mesenteric
and perinephric sites the most frequent in pelvis.3 The retroperi-
toneal location of the CD is extremely rare presenting only 7% of
cases,6 usually at the left side. In the literature in fact the ratio
between the right and left location is equal to 13:4.7 In our case the
CD was localized in the right paramediana site.
Castleman’s disease in the abdomen and pelvis is even rarer and
should be distinguished from tuberculosis of the mesentery,
lymphoma, accessory spleen, and other hypervascular lesions.
From the radiological and clinical points of view, disseminated
Castleman’s disease may be indistinguishable from lymphoma.
Ultimately, ultrasound-guided aspiration biopsy of an enlarged
lymph node or mass is recommended for histopathological
diagnosis.8
Based on the histological features Flendring and Schillings9 have
described two different variants of CD and a mixed form that Keller
et al. subsequently deﬁned as a form ialino vascular (HV) is the
plasma cell (PC) and form plamacellulare mixed ialino vascular
(HV-PC).2Fig. 2. Gross ﬁndings of lymph node.The etiology is currently unknown but it is assumed that this
disease could be a response to a chronic inﬂammatory process,4 an
amartomatoso process,10 a state of immunodeﬁciency11 or an
immune disorder.12 The Epstein-Barr Virus, Toxoplasma and
Mycobacterium tuberculosis have been considered to be involved in
the genesis of some cases of variant PC CD.2,12
Several studies in animal models and humans have focused
attention on the role of IL-6 in activation of the differentiation of
plasma cells, the proliferative processes of the lymphoid cells13 and
vascular endothelium and the onset of events involved in this
systemic disease.10
The Human Herpes Virus 8 (HHV-8) is the causative agent of
Kaposi’s sarcoma in immunosuppressed subjects,14 this virus was
also frequently found in HIVþ and patients suffering from CD15 and
so it is possible to afﬁrm that it can play an important role in the
pathogenesis of Kaposi’s sarcoma as well as the multicentric form
of CD. In our case, the patient had anti-HHV-8 and also had a history
of numerous reported incidents of herpetic infection, which could
further support the view that this virus might be somehow
involved in the pathogenesis of CD. The hypothesis that the IL-6
may play an important role in the pathogenesis of CD is supported
by the fact that the HHV-8 has a gene coding for a protein similar to
IL-6 (VIL-6)16 which could be responsible for the clinical-patho-
logical anatomy typical of CD.17Fig. 4. Microscopic ﬁndings of lymph node.
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resection, which offers the best chance for cure.18
In the near future, new treatment protocols for CD, such as anti-
interlukin-6 receptor antibody (tocilizumab) therapy,19 will be
applied.4. Conclusion
CD must be included in the differential diagnosis of retroperi-
toneal tumors even though the deﬁnitive diagnosis can only be
achieved by histological and immunohistochemical examination.
The retroperitoneal location is rare, especially if the lesion is located
on the right. In the pathogenesis of CD an important role could be
played by HHV-8 whose presence could be the stimulus that causes
the chronic inﬂammatory response in the chronic course of this CD.
In the case of single location, the treatment of choice is surgical
removal.
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